Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

OCUFLOX 0.3% EYE DROPS

ofloxacin
$22.6264per ML
High Outlier

Strength

3 mg/mL

Manufacturer

Allergan, Inc.

NDC

11980077905

Classification

Brand

Dosage Form

SOLUTION/ DROPS

Route

OPHTHALMIC

Last Updated

1/1/2018

Active Ingredients

OFLOXACIN

Approval Type

New Drug (NDA)

FDA Application

NDA019921

On Market Since

8/1/1993

Pharmacological Classes

Quinolone Antimicrobial
Quinolones

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

0.0%

5Y

0.0%

All

+15.0%

Generic Alternatives

Save up to 95%

4 alternatives • Same active ingredient

OFLOXACIN 0.3% EYE DROPS
Generic
60505056001•Apotex Corp.
$1.1535
Save 95%
OFLOXACIN 0.3% EYE DROPS
Generic
70756065030•Lifestar Pharma LLC
$1.1535
Save 95%
OFLOXACIN 0.3% EYE DROPS
Generic
00904743410•Major Pharmaceuticals
$1.1535
Save 95%
OFLOXACIN 0.3% EYE DROPS
Generic
72603019202•NorthStar Rx LLC
$1.1535
Save 95%

Related Drugs

Same classification

VIGAMOX 0.5% EYE DROPS
Brand
82667070003•Harrow Eye, LLC
$31.7719
per ML
CIPRO HC OTIC SUSPENSION
Brand
66758008770•Sandoz Inc.
$34.8706
per ML
BESIVANCE 0.6% SUSP
Brand
24208044605•Bausch & Lomb Incorporated
$44.1387
per ML
ZYMAXID 0.5% EYE DROPS
Brand
00023361525•Allergan, Inc.
$67.3765
per ML
BAXDELA 450 MG TABLET
Brand
70842010101•Melinta Therapeutics, LLC
$72.3117
per EA
BAXDELA 450 MG TABLET
Brand
70842010102•Melinta Therapeutics, LLC
$72.3117
per EA
CILOXAN 0.3% OINTMENT
Brand
66758007138•Sandoz Inc.
$74.2629
per GM

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy